Osteoporosis as a result of the long-term administration of glucocorticoids in patients suffering from acantholytic pemphigus
| Autor: | E. P. Gurkovskaya, Yu.M. Bochkarev, M. A. Ufimtseva, K. I. Nikolaeva, P. S. Puhtinskaya, O. D. Lesnaya |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Bone mineral
Pediatrics medicine.medical_specialty FRAX business.industry Osteoporosis Absolute risk reduction глюкокортикоидный остеопороз glucocorticoid-induced osteoporosis lcsh:RL1-803 medicine.disease acantholytic pemphigus Osteopenia Pemphigus Glucocorticoid therapy lcsh:Dermatology medicine акантолитическая пузырчатка In patient business |
| Zdroj: | Vestnik Dermatologii i Venerologii, Vol 0, Iss 3, Pp 56-61 (2017) |
| ISSN: | 2313-6294 0042-4609 |
| DOI: | 10.25208/0042-4609-2016-92-3-56-61 |
| Popis: | Goal. To study the prevalence of glucocorticoid-induced osteoporosis in patients suffering from acantholytic pemphigus and risk of osteoporosis-related fractures. Materials and methods. The study involved 26 patients including 12 patients suffering from acantholytic pemphigus. The patients underwent dual-energy X-ray absorptiometry (DXA) for calculating bone mineral density (BMD) as well as T and Z scores. To assess the ten-year probability (absolute risk) of fractures, the FRAX model was applied. Major results. Glucocorticoid-induced osteoporosis was diagnosed in 33.3% of the AP patients receiving a glucocorticoid therapy, and osteopenia was also diagnosed in 33.3% of them; an increased risk of osteoporosis-related fractures was observed in all of the patients over 40, which entails the need in early diagnostics of pathologic bone changes and prevention of complications such as osteoporosis-related fractures. Conclusion. A high share of complications (83.3%) related to systemic GCS stipulates the need in increased cooperation between dermatologists and allied specialists. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|